TOKYO, June 5 (Reuters) - A drug candidate critical to Takeda Pharmaceutical Co Ltd’s mainstay diabetes franchise is expected to show sufficient promise to gain approval but may not be much better than a rival medicine from Merck & Co . Takeda’s drug, called alogliptin or SYR-322, is under regulatory review and data will be presented at the American Diabetes Association’s annual meeting, which runs from June 6-10.
